19 studies found for:    "RWJMS" OR "Robert Wood Johnson Medical School" OR "Cancer Institute of New Jersey" OR "CINJ" | Open Studies | "Breast Diseases"
Show Display Options
Rank Status Study
1 Recruiting Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery
Conditions: Ductal Breast Carcinoma In Situ;   Estrogen Receptor Positive;   Invasive Breast Carcinoma;   Progesterone Receptor Positive;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer
Interventions: Radiation: Accelerated Partial Breast Irradiation;   Radiation: High-Dose Rate Brachytherapy;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
2 Recruiting Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: epirubicin hydrochloride;   Drug: carboplatin;   Procedure: therapeutic conventional surgery;   Drug: paclitaxel;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
3 Recruiting Radiation Therapy in Treating Women With Early Stage Breast Cancer
Condition: Breast Cancer
Interventions: Radiation: External beam boost;   Radiation: whole breast irradiation
4 Recruiting Virtual Weight Loss Program in Maintaining Weight in African American Breast Cancer Survivors
Conditions: Cancer Survivor;   Invasive Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Behavioral: Behavioral Dietary Intervention;   Behavioral: Exercise Intervention;   Device: Monitoring Device;   Procedure: Psychosocial Assessment and Care;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
5 Recruiting The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)
Condition: Breast Neoplasms
Intervention: Other: endocrine therapy alone without radiotherapy
6 Recruiting Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Conditions: Ductal Breast Carcinoma In Situ;   Estrogen Receptor and/or Progesterone Receptor Positive;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Multicentric Breast Carcinoma;   Multifocal Breast Carcinoma;   Synchronous Bilateral Breast Carcinoma
Interventions: Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate
7 Recruiting S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
Condition: Breast Cancer
Interventions: Drug: anastrozole;   Drug: everolimus;   Drug: exemestane;   Drug: goserelin acetate;   Drug: letrozole;   Drug: leuprolide acetate;   Drug: tamoxifen citrate;   Other: placebo
8 Recruiting Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer
Condition: Breast Cancer
Interventions: Procedure: palliative surgery;   Procedure: therapeutic conventional surgery;   Radiation: palliative radiation therapy;   Radiation: radiation therapy
9 Unknown  Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer
Condition: Breast Cancer
Interventions: Drug: tamoxifen citrate;   Other: laboratory biomarker analysis
10 Recruiting A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
Condition: Early Stage HER2+ Breast Cancer
Interventions: Drug: Neratinib;   Drug: Loperamide
11 Recruiting CC-486 (Oral Azacitidine) Bioequivalence Study in Patients With Solid Tumor or Hematologic Malignancies
Conditions: Hematological Neoplasms;   Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Lymphoma;   Multiple Myeloma;   Acute Myeloid Leukemia;   Leukemia;   Myelodysplastic Syndromes;   Neoplasms;   Melanoma;   Breast Cancer;   Metastatic Breast Cancer;   Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Glioblastoma Multiforme;   Osteosarcoma;   Sarcoma;   Thyroid Cancer;   Genitourinary
Interventions: Drug: CC-486;   Drug: Vidaza
12 Recruiting Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women
Condition: Breast Cancer
Interventions: Drug: BYL719;   Drug: BKM120;   Drug: Placebo
13 Recruiting A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
Condition: HER2+ Metastatic Breast Cancer (MBC)
Interventions: Drug: neratinib;   Drug: capecitabine;   Drug: lapatinib
14 Recruiting Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
Condition: Breast Cancer
Interventions: Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin
15 Recruiting Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Conditions: Breast Carcinoma;   Carcinoma of Unknown Primary Origin;   Endometrial Carcinoma;   Esophageal Carcinoma;   Lung Carcinoma;   Malignant Head and Neck Neoplasm;   Melanoma;   Ovarian Carcinoma;   Renal Pelvis and Ureter Urothelial Carcinoma;   Testicular Lymphoma
Interventions: Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study;   Drug: Veliparib
16 Recruiting Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
Condition: Breast Cancer
Interventions: Drug: Fulvestrant;   Drug: Alpelisib;   Drug: Alpelisib placebo
17 Recruiting Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
Conditions: Stage IB Breast Cancer;   Stage II Breast Cancer
Interventions: Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
18 Recruiting A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Condition: Metastatic Breast Cancer HR+, HER2-
Interventions: Drug: Fulvestrant;   Drug: BKM120;   Drug: BKM120 matching placebo
19 Recruiting Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Olaparib;   Drug: Placebo

Indicates status has not been verified in more than two years